Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.43 |
| ▸ | ATP4A | P20648 | 2/20 | 0.35 |
| ▸ | ATP4B | P51164 | 2/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1218640 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP2C9ATP4AATP4BPDE5A | |
| SCHEMBL5747928 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP2C9ATP4AATP4BPDE5A | |
| SCHEMBL1814134 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP2C9ATP4AATP4BPDE5A | |
| SCHEMBL5634257 | 0.87 | CYP3A4 (0.35) | CYP3A4CYP2C9 | |
| SCHEMBL1812969 | 0.87 | CYP3A4 (0.35) | CYP3A4CYP2C9 | |
| SCHEMBL4880229 | 0.86 | CYP3A4 (0.37) | CYP3A4CYP2C9ATP4AATP4BGBA1 | |
| SCHEMBL5838692 | 0.85 | CYP3A4 (0.33) | CYP3A4CYP2C9 | |
| SCHEMBL5839023 | 0.85 | CYP3A4 (0.35) | CYP3A4CYP2C9 | |
| SCHEMBL5838814 | 0.84 | CYP3A4 (0.34) | CYP3A4CYP2C9 | |
| SCHEMBL5745833 | 0.81 | CYP3A4 (0.36) | CYP3A4CYP2C9ATP4AATP4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370425-A1 | TETRAHYDROPYRIDOETHERS FOR TREATMENT OF AMD | KATAIRO GMBH (DE) | 2022-11-24 | — | — | US | disclosed |
| EP-3695838-A1 | TETRAHYDROPYRIDOETHERS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | Katairo GmbH (DE) | 2020-08-19 | — | — | EP | disclosed |
| US-20160279111-A1 | TETRAHYDROPYRIDOETHERS FOR THE TREATMENT OF AMD | TAKEDA GMBH (DE) | 2016-09-29 | — | — | US | disclosed |
| US-20160235724-A1 | TETRAHYDROPYRIDOETHERS FOR THE TREATMENT OF STARGARDT'S DISEASE | KATAIRO GMBH (DE) | 2016-08-18 | — | — | US | disclosed |
| EP-3054949-A1 | TETRAHYDROPYRIDOETHERS FOR THE TREATMENT OF STARGARDT'S DISEASE | Katairo GmbH (DE) | 2016-08-17 | — | — | EP | disclosed |
| US-9314453-B2 | Tetrahydropyridoethers for treatment of AMD | KATAIRO GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| WO-2015052256-A1 | TETRAHYDROPYRIDOETHERS FOR THE TREATMENT OF STARGARDT'S DISEASE | KATAIRO GMBH (DE) | 2015-04-16 | — | — | WO | disclosed |
| EP-2742939-A1 | Tetrahydropyridoethers for treatment of age-related macular degeneration (AMD) | Katairo GmbH (DE) | 2014-06-18 | — | — | EP | disclosed |
| EP-2249829-B1 | Tetrahydropyridoethers for treatment of age-related macular degeneration (AMD) | KATAIRO GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-20130131101-A1 | TETRAHYDROPYRIDOETHERS FOR TREATMENT OF AMD | KATAIRO GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| WO-2003016310-A1 | ALKYL-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ALTANA PHARMA AG (DE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003014120-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | ALTANA PHARMA AG (DE) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003014119-A1 | TRICYCLIC EPOXIDES | ALTANA PHARMA AG (DE) | 2003-02-20 | — | — | WO | disclosed |
| EP-1115725-B1 | TETRAHYDROPYRIDOETHERS | ALTANA PHARMA AG (DE) | 2003-01-29 | — | — | EP | disclosed |
| US-6436953-B1 | ANTISECRETORY AGENTS, GASTROINTESTINAL INFLAMMATORY DISEASES; (7R,8R,9R)-2,3-DIMETHYL-8-HYDROXY-7-METHOXY-9-PHENYL-7,8,9,10-TETRAHYDRO -IMIDAZO(1,2-H)-(1,7)NAPHTHYRIDINE | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2002-08-20 | — | — | US | disclosed |
| EP-1115725-A1 | TETRAHYDROPYRIDOETHERS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-07-18 | — | — | EP | disclosed |
| US-6197783-B1 | THERAPY FOR GASTROINTESTINAL DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-03-06 | — | — | US | disclosed |
| WO-2000017200-A1 | TETRAHYDROPYRIDOETHERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-03-30 | — | — | WO | disclosed |
| EP-0971922-A1 | TETRAHYDROPYRIDO COMPOUNDS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998042707-A1 | TETRAHYDROPYRIDO COMPOUNDS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370425-A1 | TETRAHYDROPYRIDOETHERS FOR TREATMENT OF AMD | ALDH1A2, TTPA, ADH7 | CYP3A4 1560/4885CYP2C9 3179/4885ATP4A 2734/4885 |
| US-20130131101-A1 | TETRAHYDROPYRIDOETHERS FOR TREATMENT OF AMD | PTGDR, TBXA2R, NR2E3 | CYP3A4 560/4885CYP2C9 2577/4885ATP4A 2975/4885 |
| US-20160235724-A1 | TETRAHYDROPYRIDOETHERS FOR THE TREATMENT OF STARGARDT'S DISEASE | STARD3, MPST, TPMT | CYP3A4 1177/4885CYP2C9 3719/4885ATP4A 525/4885 |
| US-20160279111-A1 | TETRAHYDROPYRIDOETHERS FOR THE TREATMENT OF AMD | NR2E3, PTGDR, TBXA2R | CYP3A4 556/4885CYP2C9 2357/4885ATP4A 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.